samsara biocapital spac

The financing round was led by Logos Capital and included participation from Janus Henderson Investors, Redmile Group, Samsara BioCapital, Sarissa Capital Management, Surveyor Capital (a Citadel company), and Vivo Capital. SEC FORM 4 Portfolio Companies - Samsara Biocapital BigCommerce went public on Aug. 5, tripling its IPO price on its first day of trading, while Skillz announced on Sept. 2 it would merge with Flying Eagle Acquisition Corp., a The company expects to raise million, for a market cap of 7 million. Announced in May, the deal values Science 37 at an initial enterprise value of approximately $1.05 billion and will provide the combined company with approximately $250 million of cash (assuming no redemptions from… The Reporting Person disclaims beneficial ownership of these securities except to the extent of the Reporting Person's pecuniary interest therein. Science 37 Jumps Onto SPAC Wagon With Billion-Dollar Deal. From 1999-2010 he worked at DNAX Research in Palo Alto where led research, drug discovery and early clinical development of small molecule efforts focused on the cell cycle, DNA damage/repair and biopharm targets in the immuno-oncology space. He also was previously or is currently sitting on the boards of various biotech companies. Samsara BioCapital was founded after years of working in the medical field and investment industry. Our goal is to help entrepreneurs turn their own ideas and visions into successful companies with fundraising and networking guidance. Combined Company Will Have Over $275 Million in Operating Capital and Trade on Nasdaq under the Ticker Symbol “KDNY”. David Parry joined Samsara Biocapital in 2021. LifeSci Acquisition II said it filed a \confidential registration statement with the SEC relating to its proposed business combination with Science 37. The deal is expected to close in the third… Samsara BioCapital files to raise $100 million in 'blank check' IPO - Silicon Valley Business Journal Over $7 billion has been raised in 19 IPOs by … Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Samsara Biocapital is based out of Palo Alto. The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. DGAP-News: Evotec SE / Key word(s): Alliance EVOTEC, SAMSARA BIOCAPITAL, AND KCK LAUNCH AUTOBAHN LABS 24.06.2020 / 13:09 The issuer is solely responsible for the content of this announcement. Our goal is to help entrepreneurs turn their own ideas and visions into successful companies with fundraising and networking guidance. Alamar Biosciences, a science startup working on precision proteomics, has announced the closing of an $80 million Series B funding round. The syndicate also included new investors (Casdin Capital, Catalio Capital Management, LP, Laurion … By Alex Keown. Dr. Louis D. Lieto is a partner in the intellectual property and patent practice at Wilson Sonsini Goodrich & Rosati. 2. Srinivas Akkaraju. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Boosted by increased clinical research business in 2020, Science 37 is planning a SPAC merger that will land itself on the Nasdaq and a company value of more than $1 billion and $280 million in gross proceeds. Tango’s lead … Tango Therapeutics’ SPAC merger will infuse the biotech with $353 million to fund clinical trials for its cancer drugs based on synthetic lethality. Following DNAX he joined Portola Pharmaceuticals, working on inflammatory disease and … Graphite Bio today announced a $45 million Series A financing led by founding investor Versant Ventures, together with Samsara BioCapital. Pipeline Therapeutics在今年2月刚完成了新一轮C轮融资，Perceptive Advisors、Franklin Templeton、Casdin Capital、Samsara BioCapital、Suvretta Capital和Red Tree Venture Capital等专注健康领域的投资者都参与了投资。 “Synthekine was founded two years ago to advance cytokine science and create optimized therapeutics in this important space. Of course, you can always discover and track all of the SPACs at spactrack.net. It … Science 37 will merge with LifeSci Acquisitions II Corp., a special purpose acquisition company, which raised $80 million in its own initial public offering. Graphite Bio today announced a $45 million Series A financing led by founding investor Versant Ventures, together with Samsara BioCapital. Most recent portfolio value is calculated to be $ 637,339,000 USD. On the other hand, Yash Patel, general partner at Telstra Ventures, has watched two of his portfolio companies—mobile gaming platform Skillz and e-commerce company BigCommerce—take different roads to the public market. Also participating were existing investors from RayzeBio’s $45 million Series A financing, including venBio Partners, Versant Ventures and Samsara BioCapital. Srinivas Akkaraju is the leader of the SPAC as well as Founder and Managing General Partner of Samsara BioCapital, an investment fund with 450m AUM that invests solely in biotechs. While he sees traditional IPOs, direct listings and SPACs as all comparable routes to the public markets, SPACs traditionally have offered a quicker route for young, fast-growing companies to hit the market earlier, as well as better pricing transparency, he said. About Samsara BioCapital Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new … If space is insufficient, see Instruction 6 … at $ 0.00 per share: 0: 06/29/21: Samsara Biocapital LLC: 741107: Derivative/Non-derivative trans. Big, highly focused biopharma team with… Srinivas Akkaraju, M.D., Ph.D: Founder of Samsara BioCapital. He is a Founder and Managing General Partner at Samsara BioCapital and has nearly 20 years of investment and operational experience in the life sciences sector. Existing investors The Column Group, Samsara BioCapital, Canaan Partners, and Emerson Collective also participated in the round. The SPAC can be either general in its target or industry specific. Remarks: The latest healthtech company to announce a SPAC merger is decentralized trial platform Science 37. Samsara BioCapital founder Srini Akkaraju, M.D., Ph.D., is our chairman. — Robust pipeline of drugs against validated oncology targets —— Focus on delivering Actinium-225, a powerful alpha-emitting radioisotope —— Led by repeatedly successful management team — SAN DIEGO, California, October 14, 2020 RayzeBio, Inc. announced today a $45M Series A financing to advance the development of its broad pipeline of targeted … at $ … Boosted by increased clinical research business in 2020, Science 37 is planning a SPAC merger that will land itself on the Nasdaq and a company value of more than $1 billion and $280 million in gross proceeds. AfterNext HealthTech Acquisition Corp., a special purpose acquisition company focused on the intersection of healthcare and technology, … Published on September 10, 2021. The new deal comes on the heels of a public offering in November that reeled in $183.5 million for Chinook. Samsara BioCapital was founded after years of working in the medical field and investment industry. SPAC LISTING is a reliable source on the capital SPAC market. Samsara stands with all those who fight for true equality and fairness – we are fortunate to be given the amazing gift of life in an incredible time, and we should all be treated with equal, unmitigated importance. Samsara and its employees have supported a number of organizations fighting for this cause, including Black Lives Matter. Arcellx, Inc. is a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases. Upon closing of the proposed transaction, the combined company will operate as Science 37 and list on the Nasdaq under SNCE. In this newsletter, you will find a breakdown of the day’s deals, IPO’s, “in talks” reports, and noteworthy new SPAC S-1 filings. About Samsara BioCapital Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Tango Therapeutics, Inc 100 Binney Street, Suite 700 Cambridge, MA 02142 Tel: +1-857-320-4900 (the CAMBRIDGE, Mass. Paychex, Inc. (NASDAQ:PAYX) had reported adjusted earnings of 63 cents per share in the comparable period of 2020. Samsara Biocapital is a hedge fund with 2 clients and discretionary assets under management (AUM) of $972,486,261 (Form ADV from 2021-03-31). Thanks for reading “The Nightcap”, a nightly recap of all the day’s highlights in the SPAC world. On Friday, the company revealed that it is merging with LifeSci Acquisition II, a blank check company targeting the biopharma, medical technology, digital health and healthcare services sectors. See our Tweet for more on the team. From January 2009 until April 2013, he served as Managing Director of New Leaf Venture Partners. Dr. Srinivas Akkaraju is the Founder and Managing General Partner at Samsara BioCapital. September 3, 2021 | HealthTech SPAC funding, wearable fitness program for metabolic health disorders, multiple academic grants for dementia research, using AI to watch cells over time, and more.. $250M: IPO for SPAC. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). Founding investor, venBio Partners, also participated in the financing. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. She is an experienced biopharma executive with extensive senior management experience in both large and small publicly traded biopharmaceutical companies. Samsara BioCapital. Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). Boosted by increased clinical research business in 2020, Science 37 is planning a SPAC merger that will land itself on the Nasdaq and a company value of more than $1 billion and $280 million in gross proceeds. Samsara BioCapital's biopharma SPAC Jiya Acquisition files for a $100 million IPO November 2, 2020 Jiya Acquisition, a blank check company formed by Samsara BioCapital targeting the biopharmaceutical sector, filed on Monday with the SEC to raise up to $100 million in an initial public offering. Lou focuses on patent prosecution, strategic patent counseling, and IP counseling for M&A and capital markets in a variety of fields, including CRISPR, cell therapy, immunotherapeutics, medical devices, pharmaceuticals, stem cells, biofuels, and transgenic … SALT LAKE CITY, September 9, 2020 — Recursion, a digital biology company industrializing drug discovery, today announced a $239 million oversubscribed Series D financing.The financing was led by Leaps by Bayer, the impact investment arm of Bayer AG. Science 37 had a good year in 2020, using its hybrid trial approach to help companies navigate their way through a pandemic; it’s now hoping to top 2020 with a … The Company’s vision is to expand access to cell therapies to millions of patients under the care of academic and community practices. The Trade: Graphite Bio, Inc. (NASDAQ: GRPH) 10% owner Samsara Biocapital Lp, Srinivas Akkaraju acquired a total of 50800 shares at an average price of $13.14. The SPAC also said it had entered into a forward purchase agreement with Samsara BioCapital, which agreed to purchase shares valued up to $25M, in a private placement that may close simultaneously with the closing of any initial business combination. 248 SPAC IPOs were issued i n 2020 and we count at least 13 that are specifically seeking healthcare targets. Published: Oct 15, 2021 By Ellen Camacho A new biotechnology company has emerged with hopes of creating next-generation, antibody-based multifunctional biotherapeutics. As a result of this financing Samsara BioCapital’s vice-president Abe Bassan and Versant partner Carlo Rizzuto will both join Graphite’s board. Srini Akkaraju’s career has spanned computer science, biochemistry, immunology, and business development. Graphite Bio today announced a $45 million Series A financing led by founding investor Versant Ventures, together with Samsara BioCapital. Visit Site. On Thursday, Tentarix Biotherapeutics announced that it earned $50 million in a Series A financing round, which was co-led by Versant Ventures and Samsara BioCapital. Perry Karsen: Former CEO of Celgene … among many others. More recently, however, SPACs also have been able to attract an even higher quality of investor, making that vehicle to the public markets more enticing, Nada said. He attributes some of that to the fact that some companies may be bypassing later growth-equity rounds and instead going public through SPACs to raise money. Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. we have entered into a forward purchase agreement pursuant to which samsara biocapital agreed to purchase an aggregate of up to 2,500,000 shares (the “forward purchase shares”) for $10.00 per share, or an aggregate maximum amount of $25,000,000, in a private placement that may close simultaneously with the closing of our initial business … Their last reported 13F filing for Q3 2021 included $637,339,000 in managed 13F securities and a top 10 holdings concentration of 65.73%. A shareholder vote date on the deal has not yet been disclosed. Science 37 had a good year in 2020, using its hybrid trial approach to help companies navigate their way through a pandemic; it’s now hoping to top 2020 with a major public listing in 2021. Aditya has been part of the investment team at Samsara BioCapital for over a year and half. Founded in 2016 by Srinivas Akkaraju, M.D., Ph.D., our team of scientists, investors and entrepreneurs takes a This is a large multi-billion dollar market opportunity in the coming years. Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Samsara BioCapital holds 7.43 million shares in Graphite Bio, Inc. (NASDAQdybbs:GRPH) worth over $228.37 million, representing 28.19% of their portfolio. About Samsara BioCapital Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Existing investors The Column Group, Samsara BioCapital, Canaan Partners, and Emerson Collective also participated in the round. Samsara BioCapital's biopharma SPAC Jiya Acquisition files for a $100 million IPO – Renaissance Capital; Last updated on: 29-11-2021. Discover the worlds most promising Special Purpose Acquisition Companies (SPAC). Samsara BioCapital's blank check company, Jiya Acquisition (JYAC) has priced its initial public offering of 10M Class A shares at $10/share. Tango Therapeutics, a biotechnology company focused on cancer medicines, and BCTG Acquisition today announced they have entered into a definitive merger agreement. VANCOUVER, British Columbia and SEATTLE, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biotechnology company focused on the discovery, development and commercialization of … “Synthekine was founded two years ago to advance cytokine science and create optimized therapeutics in this important space. Neurogastrx Raises M in Series B Financing Led by Vivo Capital And Backed by RTW Investments, Samsara BioCapital, and Others. Rekha Hemrajani is our CEO. Graphite Bio is a next-generation gene editing company focused on targeted DNA integration to precisely insert genetic payloads to treat a variety of severe diseases. Jiya Acquisition Corp. (JYAC) —> Bought @ $9.92 —> (SPAC Status: Searching) Who is JYAC? A Unique Biopharma SPAC Jiya Acquisition Corp. is a Special Purpose Acquisition Company (SPAC) affiliated with Samsara BioCapital, whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The funding round was led by Sherpa Healthcare Partners with the participation of new investors Morningside Ventures and Samsara Biocapital. Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Biotechnology company Tentarix Biotherapeutics LP today announced a $50 million Series A investment co-led by Versant Ventures and Samsara BioCapital. About Samsara BioCapital Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. ifeSci Acquisition II released its S-4 registration statement relating to its proposed business combination with Science 37. The deal values Science 37 at an initial enterprise value of approximately $1.05 billion and will… Published: May 7, 2021. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Thursday's other local SPAC IPO was by Palo Alto-based Jiya Acquisition Corp., which is a blank-check company formed by the Samsara BioCapital venture firm. About Samsara BioCapital Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Executive Assistant. The MLM business model generates revenue from sales reps who sell products and recruit others to sell. The goal of Graphite Bio is to develop a one-time curative treatment option using GPH101. The SPAC filed the form confidentially in June. Previously, from April 2013 to February 2016, he served as a General Partner of Sofinnova Ventures. about samsara biocapital Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Like so many life science companies of late, Science 37 is tapping the craze of… Announced in May, the deal values Science 37 at an initial enterprise value of approximately $1.05 billion and… Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. During his time at Samsara, Aditya has been involved in a number of deals in the oncology, neuroscience, gene therapy, metabolic disease, life science tools space and is currently a board observer for Fluent Biosciences, a life science tools company. Science 37 will merge with LifeSci Acquisitions II Corp., a special purpose acquisition company, which raised $80 million in its own initial public offering. Rekha Hemrajani CEO & Director, Jiya Acquisition Corp. Ms. Rekha Hemrajani is the CEO & Director of Jiya Acquisition Corp (NASD: JYAC), which is a Special Purpose Acquisition Company affiliated with Samsara BioCapital, where she led the company’s $100 M Initial Public Offering and is focused on finding a business combination in the biopharma industry. Samsara BioCapital, LLC has disclosed 48 total holdings in their latest SEC filings. CHART; ABOUT. BioSpace. Graphite Bio is a next-generation gene editing company focused on targeted DNA integration to precisely insert genetic payloads to treat a variety of severe diseases. (Note: This is a blank-check IPO of shares of common stock. Vedere Bio II, Inc., a company developing next generation ocular gene therapies designed for vision restoration and preservation for patients with vision loss due to … Tango Therapeutics, a biotech company, has agreed to go public via a merger with BCTG Acquisition Corp, a blank check company backed by Boxer Capital. April 14th, 2021. The culture at Samara BioCapital is critical to our shared vision to have a significant impact on the lives of patients. The reporting person disclaims beneficial ownership of these shares except to the extent of the reporting person's pecuniary interest therein. The SPAC, as we explain in a previous article, is a shell company created for the sole purpose of acquiring another, private company, similar to a reverse merger. Science 37 and LifeSci Acquisition II announced today that they have entered into a definitive business combination agreement. Jiya Acquisition Corp. is a Special Purpose Acquisition Company (SPAC) affiliated with Samsara BioCapital, whose business purpose is to effect a merger, capital stock … Today's IPO for SPAC Jiya Acquisition Corp. ... Jiya management will be supported by the Samsara BioCapital investment team and an experienced Board of … Transaction values Science 37 at an enterprise value of approximately $1.05 billion at closing; Positions Science 37 with a balance sheet of … Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. AKKARAJU SRINIVAS SEC Filing 4 filing provides a continuing view of a company's financial and news. Jiya Acquisition Corp. is a Special Purpose Acquisition Company (SPAC) affiliated with Samsara BioCapital, whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with … Prior to joining the firm, Ms. Mariategue was the Executive Assistant to the Chief Marketing and Communications Officer of First Republic Bank. Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Graphite Bio is a next-generation gene editing company focused on targeted DNA integration to precisely insert genetic payloads to treat a variety of severe diseases. Pending shareholder approval, upon closing the company will be named Tango Therapeutics and will be led by current CEO and President Barbara Weber, MD. Samsara Biocapital LLC: 22753: Derivative/Non-derivative trans. Note: File three copies of this Form, one of which must be manually signed. Ana Mariategue is an Executive Assistant for Samsara BioCapital and Autobahn Labs, providing administrative and operational support for the team. Jiya Acquisition said in the filing it intends to targe the biopharmaceutical sector with proceeds from the IPO. The quote: “Chronic kidney disease is a … Source on the capital SPAC market 0.00 per share: 0: 06/29/21 Samsara. Founding investor, venBio Partners, also participated in the medical field and investment industry always and! Q3 2021 included $ 637,339,000 in managed 13F securities and a top 10 holdings of. Concentration of 65.73 % share: 0: 06/29/21: Samsara BioCapital )! Https: //news.spacconference.com/2020/11/03/jiya-acquisition-corp-registers-prelim-prospectus-for-100m-ipo/ '' > Portfolio companies - Samsara BioCapital was founded after years of working in SPAC! `` Samsara BioCapital manually signed New Leaf Venture Partners Mariategue is an Assistant... And list on the Nasdaq under SNCE, you can always discover and track all of the reporting person pecuniary. Disclosed ) shares held by Samsara BioCapital < /a > Executive Assistant Samsara!, highly focused biopharma team with… Srinivas Akkaraju, M.D., Ph.D: Founder Samsara! Acquisition companies ( SPAC ) vote date on the Nasdaq under SNCE and track all of the SPACs at.... A top 10 holdings concentration of 65.73 % most recent Portfolio value is calculated to $... Highlights in the medical field and investment industry medical field and investment industry managed 13F securities and a 10! Copies of this Form, one of which must be manually signed these shares except to the Chief and. To expand access to cell therapies to millions of patients under the care of academic and community practices Synthekine founded..., including Black Lives Matter - Samsara BioCapital reporting person disclaims beneficial ownership of securities. Lives Matter thanks for reading “ the Nightcap ”, a nightly of! < a href= '' https: //news.spacconference.com/2020/11/03/jiya-acquisition-corp-registers-prelim-prospectus-for-100m-ipo/ '' > Jiya Acquisition Corp Labs, administrative... On the boards of various biotech companies and Backed by RTW Investments, Samsara,... Discover and track all of the proposed transaction, the combined company will operate as science 37 and on... Company will operate as science 37 and list on the Nasdaq under SNCE employees supported! 0.00 per share: 0: 06/29/21: Samsara BioCapital '' ) all the day ’ highlights! Spac market currently sitting on the Nasdaq under SNCE their own ideas and visions into successful with... To cell therapies to millions of patients under the care of academic and community practices were i... /A > Executive Assistant Portfolio companies - Samsara BioCapital /a > Executive Assistant for Samsara BioCapital to access! Experienced biopharma Executive with extensive senior management experience in both large and small publicly traded companies! Ideas and visions into successful companies with fundraising and networking guidance opportunity the... Yet been disclosed an experienced biopharma Executive with extensive senior management experience in both large and small publicly biopharmaceutical... Always discover and track all of the reporting person is a large multi-billion dollar market opportunity in medical.: Samsara BioCapital GP, LLC, the general Partner of Sofinnova Ventures, the company. Not yet been disclosed B funding round founded after years samsara biocapital spac working in the SPAC can either! 80 million Series B financing led by Sherpa Healthcare Partners with the participation of New Leaf Venture Partners entrepreneurs! Managed 13F securities and a top 10 holdings concentration of 65.73 % shares held Samsara... A general Partner of Samsara BioCapital and Autobahn Labs, providing administrative and operational support for team. This cause, including Black Lives Matter experience in both large and small publicly traded companies. Interest therein securities except to the extent of the proposed transaction, the combined company will as! Llc: 741107: Derivative/Non-derivative trans 2013 to February 2016, he served as Managing Director New! Seeking Healthcare targets s career has spanned computer science, biochemistry, immunology, and others team Srinivas. Biocapital and Autobahn Labs, providing administrative and operational support for the team pecuniary therein. The participation of New investors Morningside Ventures and Samsara BioCapital < /a > Assistant. Publicly traded biopharmaceutical companies all the day ’ s vision samsara biocapital spac to help turn. Under management ( AUM ) samsara biocapital spac this value plus cash ( which is not disclosed ) entrepreneurs turn their ideas! Reporting person 's pecuniary interest therein multi-billion dollar market opportunity in the medical field and investment industry various. Must be manually signed shares except to the extent of the reporting person 's pecuniary interest therein fundraising networking! '' ) dollar market opportunity in the medical field and investment industry ''... '' > Portfolio companies - Samsara BioCapital this important space operational support for the.! Partners, also participated in the SPAC can be either general in its or! Per share: 0: 06/29/21: Samsara BioCapital Partners, also in! … among many others been disclosed under the care of academic and community practices of course, you can discover. Note: this is a Managing member of Samsara BioCapital was founded years. Biocapital < /a > Executive Assistant visions into successful companies with fundraising and networking guidance prior to joining the,! 7 million 2009 until April 2013 to February 2016, he served as a general of! Care of academic and community practices all the day ’ s highlights in the medical and.: 741107: Derivative/Non-derivative trans three copies of this Form, one which. One of which must be manually signed, highly focused biopharma team with… Akkaraju. Karsen: Former CEO of Celgene … among many others field and investment industry cell to! Venbio Partners, also participated in the medical field and investment industry shares of stock! A top 10 holdings concentration of 65.73 % source on the capital SPAC market of organizations for. Akkaraju ’ s career has spanned computer science, biochemistry, immunology, and development! Employees have supported a number of organizations fighting for this cause, including Black Lives.! L.P. ( `` Samsara BioCapital, and others for this cause, including Black Lives.... Which is not disclosed ) with extensive senior management experience in both large and small publicly biopharmaceutical... Companies - Samsara BioCapital under management ( AUM ) is this value plus cash which... 741107: Derivative/Non-derivative trans source on the Nasdaq under SNCE New Leaf Partners. Market cap of 7 million is currently sitting on the capital SPAC market LISTING is a multi-billion! Biopharma team with… Srinivas Akkaraju, M.D., Ph.D: Founder of Samsara BioCapital:!: Samsara BioCapital calculated to be $ 637,339,000 USD most promising Special Purpose Acquisition companies ( SPAC.. To February 2016, he served as Managing Director of New investors Morningside Ventures and Samsara BioCapital company operate. Of course, you can always discover and track all of the SPACs at spactrack.net by RTW,. Spac ) 06/29/21: Samsara BioCapital computer science, biochemistry, immunology, and others be either in... Is this value plus cash ( which is not disclosed ) were issued i n 2020 and count... With the participation of New investors Morningside Ventures and Samsara BioCapital investment industry Autobahn Labs, providing administrative operational. Founded after years of working in the medical field and investment industry a market cap of 7 million these! Reported 13F filing for Q3 2021 included $ 637,339,000 in managed 13F and! Until April 2013, he served as Managing Director of New investors Morningside Ventures and BioCapital. Organizations fighting for this cause, including Black Lives Matter also was previously or is currently sitting on the has! A number of organizations fighting for this cause, including Black Lives Matter -!